The three-decade long journey in heart failure drug development

KS Lewis, J Butler, J Bauersachs, P Sandner - Heart Failure, 2017 - Springer
Heart failure is a global disease with increasing prevalence due to an aging worldwide
population with increasing co-morbidities. Despite several therapeutic options available to …

Ischemic left ventricle systolic dysfunction: an evidence-based approach in diagnostic tools and therapeutics

EG Lima, FPC Carvalho, JPP Linhares Filho… - Revista da Associação …, 2017 - SciELO Brasil
Coronary artery disease (CAD) associated with left ventricular systolic dysfunction is a
condition related to poor prognosis. There is a lack of robust evidence in many aspects …

The effect of candesartan on pentraxin-3 plasma levels as marker of endothelial dysfunction in patients with essential arterial hypertension

V Buda, M Andor, C Cristescu, M Voicu… - Irish Journal of Medical …, 2017 - Springer
Background In the last decades, the studies performed on the field of endothelial dysfunction
confirmed the fact that the starting point of this pathology is the inflammation. Several …

Liguzinediol enhances the inotropic effect of rat hearts via inhibition of protein phosphatase (PP1 and PP2A) activities

S Li, H Huang, M Zhang, W Wang, S Xue… - Journal of …, 2017 - journals.lww.com
It has been demonstrated that liguzinediol (2, 5-dihydroxymethyl-3, 6-dimethylpyrazine,
LZDO), a derivative of ligustrazine from Ligusticum wallichii Franch, exerts positive inotropy …

Elastase‐2, an angiotensin II‐generating enzyme, contributes to increased angiotensin II in resistance arteries of mice with myocardial infarction

C Becari, MAB Silva, MT Durand… - British Journal of …, 2017 - Wiley Online Library
Background and Purpose Angiotensin II (Ang II), whose generation largely depends on
angiotensin‐converting enzyme (ACE) activity, mediates most of the renin‐angiotensin …

A review of chemical therapies for treating diabetic hypertension

PA Sarafidis, ME Alexandrou… - Expert opinion on …, 2017 - Taylor & Francis
Introduction: Hypertension and diabetes are two of the most important modifiable risk factors
for cardiovascular and renal disease. The majority of patients with diabetes also have high …

[PDF][PDF] Tratamento farmacológico para insuficiência cardíaca sistólica crônica e as evidências disponíveis: uma revisão narrativa da literatura

CC Mizzaci, R Rieira, ALC Martimbianco - Diagn Tratamento, 2017 - docs.bvsalud.org
Introdução: A insuficiência cardíaca é uma síndrome clínica complexa de caráter sistêmico,
definida como disfunção cardíaca que ocasiona inadequado suprimento sanguíneo para …

[HTML][HTML] Induction of Type 2 diabetes mellitus with antihypertensive therapy: is there any role of alpha adducin, ACE, and IRS-1 gene?

S Gupta, V Jhawat - Value in health regional issues, 2017 - Elsevier
Hypertension and diabetes are related disorders that share common pathophysiological
pathways and occur together. Although hypertension itself is a risk factor for developing …

The impact of cardiovascular drugs on glycemic control: a review

A Grodzinsky, SV Arnold, D Jacob, B Draznin… - Endocrine Practice, 2017 - Elsevier
Objective: The prevalence of diabetes mellitus (DM) is steadily rising in the US, both in the
general population and among those with cardiovascular disease (CVD). Understanding …

[HTML][HTML] How to improve adherence to life-saving heart failure treatments with potassium binders

M Lainscak - Cardiac Failure Review, 2017 - ncbi.nlm.nih.gov
Medications that affect the renin–angiotensin–aldosterone system (RAAS) form the mainstay
of current heart failure (HF) therapy in patients with reduced ejection fraction. Concerns …